Anthem Biosciences Limited (BOM:544449)

Market Cap	433.98B
Revenue (ttm)	20.52B
Net Income (ttm)	5.05B
Shares Out	n/a
EPS (ttm)	8.99
PE Ratio	85.99
Forward PE	69.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,180
Average Volume	32,832
Open	760.15
Previous Close	770.10
Day's Range	760.15 - 777.05
52-Week Range	701.75 - 873.25
Beta	n/a
RSI	42.18
Earnings Date	Nov 13, 2025

About Anthem Biosciences

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial...

• Industry: Commercial Physical and Biological Research
• Founded: 2006
• Employees: 1,825
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544449

Financial Performance

In 2024, Anthem Biosciences's revenue was 18.50 billion, an increase of 30.29% compared to the previous year's 14.20 billion. Earnings were 4.51 billion, an increase of 22.86%.